Screener
Haemonetics HAE MedSurg — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
FAQ
- What is Haemonetics's medsurg — D&A?
- Haemonetics (HAE) reported medsurg — D&A of $13.48M in Q2 2026.
- What does medsurg — D&A mean?
- This metric reflects the non-cash expense allocated to the systematic reduction in the value of tangible and intangible assets associated with the medical and surgical segment over their useful lives. It provides insight into the capital intensity of the segment and the ongoing investment required to maintain its operational infrastructure. Monitoring this helps analysts understand the segment's underlying cash flow generation capacity relative to its asset base.
Ask your AI about Haemonetics's medsurg — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude